J Thromb Haemost:艾多沙班、利伐沙班和阿哌沙班在静脉血栓栓塞患者中的疗效和安全性比较

2022-06-28 MedSci原创 MedSci原创

在常规治疗中,依度沙班、利伐沙班和阿哌沙班似乎在治疗VTE方面具有相似的有效性和安全性。

尽管有几项研究比较了利伐沙班和阿哌沙班在静脉血栓栓塞(VTE)患者中的有效性和安全性,但缺乏将这些药物与依度沙班的直接比较。

近日,血栓和凝血疾病权威杂志Journal of Thrombosis and Haemostasis上发表了一篇研究文章,研究人员旨在比较依度沙班、利伐沙班和阿哌沙班在VTE患者中的有效性和安全性。

在这项使用日本医院管理数据库的回顾性队列研究中,研究人员确定了三组VTE患者,他们开始使用依度沙班、利伐沙班或阿哌沙班进行治疗。该研究的主要有效性结局为复发性VTE,主要安全性结局是颅内出血和胃肠道出血的复合结局。受试者被随访长达180天,研究人员使用倾向得分匹配权重平衡组间的基线特征。

研究人员确定了3369名艾多沙班、1592名利伐沙班和1998名阿哌沙班治疗者。三种药物在预防复发性VTE(艾多沙班 vs 利伐沙班调整后的发病率比[aIRR]为0.77;95%置信区间[CI]为0.45至1.30;艾多沙班 vs 阿哌沙班相比aIRR为0.92;95%CI为0.54至1.56;利伐沙班 vs 阿哌沙班的IRR为1.20;95%CI为0.69至2.10)或颅内出血或胃肠道出血的风险(艾多沙班 vs 利伐沙班相比的aIRR为1.57;95%CI为0.85至2.90;艾多沙班 vs 阿哌沙班的IRR为1.30;95%CI为0.76至2.23;利伐沙班 vs 阿哌沙班的IRR为0.83;95%CI为0.42至1.64)方面没有显著差异。

由此可见,在常规治疗中,依度沙班、利伐沙班和阿哌沙班似乎在治疗VTE方面具有相似的有效性和安全性。

 

原始出处:
 
Toshiki Fukasawa.et al.Comparative effectiveness and safety of edoxaban, rivaroxaban, and apixaban in patients with venous thromboembolism: a cohort study.Journal of Thrombosis and Haemostasis.2022.https://onlinelibrary.wiley.com/doi/10.1111/jth.15799.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1955598, encodeId=36c519555988f, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Mar 23 01:32:55 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008590, encodeId=f1a2200859081, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sat Sep 17 19:32:55 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721206, encodeId=459d1e212067e, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Mon Oct 03 05:32:55 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698390, encodeId=f7751698390aa, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Jul 08 07:32:55 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241566, encodeId=8360124156664, content=<a href='/topic/show?id=4e7386e5810' target=_blank style='color:#2F92EE;'>#艾多沙班#</a>、<a href='/topic/show?id=decb3226811' target=_blank style='color:#2F92EE;'>#利伐沙班#</a>和<a href='/topic/show?id=95089e7452f' target=_blank style='color:#2F92EE;'>#阿哌沙班#</a>在<a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a><a href='/topic/show?id=23c58911686' target=_blank style='color:#2F92EE;'>#血栓栓塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86758, encryptionId=4e7386e5810, topicName=艾多沙班), TopicDto(id=32268, encryptionId=decb3226811, topicName=利伐沙班), TopicDto(id=97745, encryptionId=95089e7452f, topicName=阿哌沙班), TopicDto(id=99179, encryptionId=5471991e9f3, topicName=静脉血栓栓塞), TopicDto(id=89116, encryptionId=23c58911686, topicName=血栓栓塞)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sun Aug 28 15:06:15 CST 2022, time=2022-08-28, status=1, ipAttribution=)]
    2023-03-23 xue8602
  2. [GetPortalCommentsPageByObjectIdResponse(id=1955598, encodeId=36c519555988f, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Mar 23 01:32:55 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008590, encodeId=f1a2200859081, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sat Sep 17 19:32:55 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721206, encodeId=459d1e212067e, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Mon Oct 03 05:32:55 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698390, encodeId=f7751698390aa, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Jul 08 07:32:55 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241566, encodeId=8360124156664, content=<a href='/topic/show?id=4e7386e5810' target=_blank style='color:#2F92EE;'>#艾多沙班#</a>、<a href='/topic/show?id=decb3226811' target=_blank style='color:#2F92EE;'>#利伐沙班#</a>和<a href='/topic/show?id=95089e7452f' target=_blank style='color:#2F92EE;'>#阿哌沙班#</a>在<a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a><a href='/topic/show?id=23c58911686' target=_blank style='color:#2F92EE;'>#血栓栓塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86758, encryptionId=4e7386e5810, topicName=艾多沙班), TopicDto(id=32268, encryptionId=decb3226811, topicName=利伐沙班), TopicDto(id=97745, encryptionId=95089e7452f, topicName=阿哌沙班), TopicDto(id=99179, encryptionId=5471991e9f3, topicName=静脉血栓栓塞), TopicDto(id=89116, encryptionId=23c58911686, topicName=血栓栓塞)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sun Aug 28 15:06:15 CST 2022, time=2022-08-28, status=1, ipAttribution=)]
    2022-09-17 changfy
  3. [GetPortalCommentsPageByObjectIdResponse(id=1955598, encodeId=36c519555988f, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Mar 23 01:32:55 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008590, encodeId=f1a2200859081, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sat Sep 17 19:32:55 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721206, encodeId=459d1e212067e, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Mon Oct 03 05:32:55 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698390, encodeId=f7751698390aa, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Jul 08 07:32:55 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241566, encodeId=8360124156664, content=<a href='/topic/show?id=4e7386e5810' target=_blank style='color:#2F92EE;'>#艾多沙班#</a>、<a href='/topic/show?id=decb3226811' target=_blank style='color:#2F92EE;'>#利伐沙班#</a>和<a href='/topic/show?id=95089e7452f' target=_blank style='color:#2F92EE;'>#阿哌沙班#</a>在<a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a><a href='/topic/show?id=23c58911686' target=_blank style='color:#2F92EE;'>#血栓栓塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86758, encryptionId=4e7386e5810, topicName=艾多沙班), TopicDto(id=32268, encryptionId=decb3226811, topicName=利伐沙班), TopicDto(id=97745, encryptionId=95089e7452f, topicName=阿哌沙班), TopicDto(id=99179, encryptionId=5471991e9f3, topicName=静脉血栓栓塞), TopicDto(id=89116, encryptionId=23c58911686, topicName=血栓栓塞)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sun Aug 28 15:06:15 CST 2022, time=2022-08-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1955598, encodeId=36c519555988f, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Mar 23 01:32:55 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008590, encodeId=f1a2200859081, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sat Sep 17 19:32:55 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721206, encodeId=459d1e212067e, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Mon Oct 03 05:32:55 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698390, encodeId=f7751698390aa, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Jul 08 07:32:55 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241566, encodeId=8360124156664, content=<a href='/topic/show?id=4e7386e5810' target=_blank style='color:#2F92EE;'>#艾多沙班#</a>、<a href='/topic/show?id=decb3226811' target=_blank style='color:#2F92EE;'>#利伐沙班#</a>和<a href='/topic/show?id=95089e7452f' target=_blank style='color:#2F92EE;'>#阿哌沙班#</a>在<a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a><a href='/topic/show?id=23c58911686' target=_blank style='color:#2F92EE;'>#血栓栓塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86758, encryptionId=4e7386e5810, topicName=艾多沙班), TopicDto(id=32268, encryptionId=decb3226811, topicName=利伐沙班), TopicDto(id=97745, encryptionId=95089e7452f, topicName=阿哌沙班), TopicDto(id=99179, encryptionId=5471991e9f3, topicName=静脉血栓栓塞), TopicDto(id=89116, encryptionId=23c58911686, topicName=血栓栓塞)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sun Aug 28 15:06:15 CST 2022, time=2022-08-28, status=1, ipAttribution=)]
    2022-07-08 fusion
  5. [GetPortalCommentsPageByObjectIdResponse(id=1955598, encodeId=36c519555988f, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Mar 23 01:32:55 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008590, encodeId=f1a2200859081, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sat Sep 17 19:32:55 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721206, encodeId=459d1e212067e, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Mon Oct 03 05:32:55 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698390, encodeId=f7751698390aa, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Jul 08 07:32:55 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241566, encodeId=8360124156664, content=<a href='/topic/show?id=4e7386e5810' target=_blank style='color:#2F92EE;'>#艾多沙班#</a>、<a href='/topic/show?id=decb3226811' target=_blank style='color:#2F92EE;'>#利伐沙班#</a>和<a href='/topic/show?id=95089e7452f' target=_blank style='color:#2F92EE;'>#阿哌沙班#</a>在<a href='/topic/show?id=5471991e9f3' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞#</a><a href='/topic/show?id=23c58911686' target=_blank style='color:#2F92EE;'>#血栓栓塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86758, encryptionId=4e7386e5810, topicName=艾多沙班), TopicDto(id=32268, encryptionId=decb3226811, topicName=利伐沙班), TopicDto(id=97745, encryptionId=95089e7452f, topicName=阿哌沙班), TopicDto(id=99179, encryptionId=5471991e9f3, topicName=静脉血栓栓塞), TopicDto(id=89116, encryptionId=23c58911686, topicName=血栓栓塞)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sun Aug 28 15:06:15 CST 2022, time=2022-08-28, status=1, ipAttribution=)]

相关资讯

Lancet:房颤患者采用新型FXIa小分子抑制剂Asundexian预防卒中的效果和安全性

房颤患者采用新型FXIa小分子抑制剂Asundexian预防卒中的效果不劣于阿哌沙班,且安全性好

JAMA:65岁以上老年房颤患者的抗凝药首选——阿哌沙班在出血及缺血事件方面均优于利伐沙班

对于65岁以上房颤患者,接受阿哌沙班治疗的主要缺血或出血事件风险均低于利伐沙班,推荐阿哌沙班作为房颤患者抗凝药物的首选。

JAMA:接受超过90天华法林、利伐沙班或阿哌沙班治疗的VTE患者疗效及不良事件风险差异

对于出院后需接受长期口服抗凝药物治疗的静脉血栓患者,与华法林和利伐沙班相比,阿哌沙班长期治疗在降低复发性静脉血栓风险方面更有效。华法林、利伐沙班以及阿哌沙班在出血风险方面的差异不显著。

Eur Heart J:Ciraparantag能逆转阿哌沙班和利伐沙班的抗凝血活性

Ciraparantag是一种抗凝剂(包括直接口服抗凝剂)的逆转剂。两项随机、安慰剂对照、剂量范围试验评估了ciraparantag逆转阿哌沙班或利伐沙班在健康老年人中诱导的抗凝治疗的疗效和安全性。

JAMA Cardiol:特殊房颤患者的抗凝选择

与VKA相比,采用阿哌沙班治疗的患者的出血、死亡或住院率较低

Lancet:新型XIa抑制剂asundexian比阿哌沙班在心房颤动患者中更加安全

与标准剂量的阿哌沙班相比,FXIa抑制剂atsundexian的剂量为20、50mg,对心房颤动患者的体内FXIa抑制接近完全,出血率较低。